Über diesen Podcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
270 Folgen · Levenswetenschappen
BioSpace
Neueste FolgeThe decisions behind scientific progress
Über diesen Podcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Neue Folgen
- J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback14. Okt. · 20 Min.
- Beyond equity: Why venture debt is reshaping European biotech8. Okt. · 23 Min.
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more7. Okt. · 24 Min.
- The race for access: How the FAIR Act could reclaim U.S. biotech leadership1. Okt. · 20 Min.
- AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll30. Sept. · 20 Min.
- How radioligand therapy is rewriting cancer care24. Sept. · 16 Min.
- Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz23. Sept. · 21 Min.
- When vision fades: Rethinking wet AMD and the durability gap17. Sept. · 22 Min.
- FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival16. Sept. · 22 Min.
- Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease9. Sept. · 20 Min.
sharemy.show/de/biospace
Für ein Plakat oder eine Folie.